SILEXION THERAPEUTICS CORP (SLXN)
Silexion Therapeutics Receives Approval from Germanys BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics Receives Approval from Germanys BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical